How our partnership with Lyniate will enhance BrightInsight’s interoperability

Brightinsight ecosystem example dark

As part of our ongoing commitment to interoperability, we are pleased to recently announce a strategic partnership with Lyniate, a global leader in healthcare data interoperability. Lyniate Envoy’s seamless data exchange capabilities will increase the value and impact of the regulated digital health solutions hosted on the BrightInsight Platform.

Lyniate’s proven technology, experienced team, and flexible deployment options make it an ideal partner for BrightInsight. Ranked Best in KLAS® for 13 consecutive years, it has been part of an impressive 7,000 healthcare information-sharing deployments across 60 countries.

This understanding of workflows in and around the EHR, along with industry standards experience, including FHIR, HL7, X12, CCD, C-CDA, MFT, and others, will help our biopharma and medtech clients connect data from any source to any destination in any format, overcoming data-sharing barriers.

Leading biopharma and medtech companies rely on BrightInsight and our Disease Management Solution to help patients more easily manage their conditions. With more patient apps being used in clinical settings, seamless integration helps:

BrightInsight’s Connected Diagnostics Platform automates lab workflows for In Vitro Diagnostics manufacturers. Lyniate will bring an integrated experience with Lab Information Systems (LIS)for lab users and more usage information and clinical insights for manufacturers.

Our work with Lyniate is an important milestone in the newly launched BrightInsight Ecosystem, bringing together the world’s leading healthcare and technology companies to put the patient at the center of care through digital health solutions. BrightInsight will be the underlying infrastructure for biopharma and medtech regulated digital health solutions, which require a reputable, flexible, data integration solution.

Lyniate wholly aligns with us on security and patient privacy and shares the same commitment to customer success. Through this partnership, we can connect Software as a Medical Device (SaMD) solutions to healthcare organizations worldwide, a critical requirement for biopharma and medtech companies.

Our teams are currently migrating interfaces to the Lyniate platform, which are planned to go live with BrightInsight customer selected sites before the end of 2022. We look forward to sharing milestones as we enter the new year.

Back to Blog